Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

Q3 2025 Management View Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." ...

Finally, add Recursion Pharmaceuticals (NASDAQ: RXRX) to your list of growth stocks to invest in right now if you've got $1,000 you're ready to put to work and don't mind taking a little risk.

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

Advanced simulations have been the subject of fiction from The Matrix to the season two episode of The Twilight Zone (2019), ...

But stablecoin's future might hinge on whether it becomes mainstream digital money for low-cost payments or a tool for a growing universe of risky leveraged finance. For widespread stablecoin adoption ...

As the Pentagon invests in agentic AI and GPS-free positioning, engineers are fielding systems that can verify identity, ...

In some cases, incentives designed to drive adoption could even push stablecoins into riskier territory, encouraging people to treat them more like speculative assets than money. New research from the ...